Drug intelligence / Profile preview

CY150112

Development stage: Phase 1
Lead developer: Jiangsu Nhwa Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

CY150112 is an oral small molecule therapeutic under development by Jiangsu Nhwa Pharmaceutical for the treatment of schizophrenia. It is currently being evaluated in early-phase clinical trials to assess its safety, tolerability, and pharmacokinetic properties in healthy adult subjects. The precise mechanism of action has not been disclosed publicly, but it represents a novel approach within the antipsychotic drug development landscape.

Other names: CY 150112CY150112CY-150112

Beyond the preview

Go deeper on CY150112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CY150112.

Explore the full profile